" class="no-js "lang="en-US"> Martin Lauriot Prevost - Medtech Alert
Sunday, September 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Martin Lauriot Prevost

Martin Lauriot Prevost

About Martin Lauriot Prevost

Martin Lauriot Prevost is the co-founder of Ozyme, which he managed between 1984 and 2021.

learn more

The company specializes in the distribution of products for molecular biology, cell biology and immunology. Martin has dual expertise in biology and genetics, and in business management, with degrees in the two areas from the University of Paris VI, France.
Today, Martin works on innovative projects in life sciences as well as impactful projects in the digital field.

Related Story

Appointments

 Nosopharm Welcomes New Members To Supervisory Board | Pharmtech Focus

Nosopharm Welcomes New Members To Supervisory Board

July 12 2022

Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, […]